-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
Lifecore Biomedical
- The Trade: Lifecore Biomedical, Inc. (NASDAQ:LFCR) 10% owner Joshua Landes acquired a total of 627,746 shares an average price of $7.97. To acquire these shares, it cost around $5 million.
- What's Happening: Lifecore Biomedical recently received notice from Nasdaq regarding delayed quarterly report.
- What Lifecore Biomedical Does: Lifecore Biomedical, incorporated in 1986, operates as an integrated contract development and manufacturing organization in the United States and internationally..
Zymeworks
- The Trade: Zymeworks Inc. (NASDAQ:ZYME) 10% owner Ecor Capital LLC acquired a total of 985,100 shares at an average price of $9.84. To acquire these shares, it cost around $9.7 million.
- What's Happening: Zymeworks recently issued corporate update on key strategic priorities and outlook for 2023.
- What Zymeworks Does: Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics.
Don't forget to check out our premarket coverage here
Neogen
- The Trade: Neogen Corporation (NASDAQ:NEOG) Chief Operating Officer Edward Douglas Jones bought a total of 2,500 shares at an average price of $17.91. To acquire these shares, it cost around $44.77 thousand.
- What's Happening: Neogen recently reported better-than-expected Q2 results.
- What Neogen Does: Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety.
Check This Out: Investor Optimism Declines As Nasdaq Snaps 7-Day Win Streak
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
儘管美國股市周三收盤走低,但仍有一些值得注意的內幕交易。
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
當業內人士購買股票時,表明他們對公司前景的信心,或者他們將股票視為便宜貨。無論哪種方式,這都標誌著有機會走多頭股票。內幕購買不應被視為作出投資或交易決定的唯一指標。在最好的情況下,它可以將信念借給購買決定。
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
以下是最近幾個值得注意的內幕購買。欲了解更多信息,請查看 本辛加的內幕交易 平台。
Lifecore Biomedical
生物醫學
- The Trade: Lifecore Biomedical, Inc. (NASDAQ:LFCR) 10% owner Joshua Landes acquired a total of 627,746 shares an average price of $7.97. To acquire these shares, it cost around $5 million.
- What's Happening: Lifecore Biomedical recently received notice from Nasdaq regarding delayed quarterly report.
- What Lifecore Biomedical Does: Lifecore Biomedical, incorporated in 1986, operates as an integrated contract development and manufacturing organization in the United States and internationally..
- 貿易: 生物醫學股份有限公司 (納斯達克:LFCR) 10% 所有者約書亞蘭德斯 購入合共 627,746 股股份 平均價格為 7.97 美元。要收購這些股份,成本約為 500 萬元。
- 發生了什麼事: 力科生物醫藥最近收到納斯達克有關延遲季度報告的通知。
- 生物醫學的作用是什麼: Lifeore 生物醫學公司成立於 1986 年,在美國和國際上是一家綜合合同開發和製造組織。
Zymeworks
子工程
- The Trade: Zymeworks Inc. (NASDAQ:ZYME) 10% owner Ecor Capital LLC acquired a total of 985,100 shares at an average price of $9.84. To acquire these shares, it cost around $9.7 million.
- What's Happening: Zymeworks recently issued corporate update on key strategic priorities and outlook for 2023.
- What Zymeworks Does: Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics.
- 貿易: 合美工股份有限公司 (納斯達克:ZYME)10% 所有者易科資本有限責任公司 在以下地區購入合共 985,100 股股份 平均價格為 9.84 美元。要收購這些股份,成本約為 970 萬美元。
- 發生了什麼事: Zymeworks 最近發布了有關 2023 年關鍵戰略重點和展望的企業最新消息。
- 什麼合金是做的: Zymeworks BC Inc 是一家臨床階段的生物製藥公司,致力於下一代多功能生物治療藥物的發現,開發和商業化。
Don't forget to check out our premarket coverage here
不要忘記在這裡查看我們的售前覆蓋範圍
Neogen
新生
- The Trade: Neogen Corporation (NASDAQ:NEOG) Chief Operating Officer Edward Douglas Jones bought a total of 2,500 shares at an average price of $17.91. To acquire these shares, it cost around $44.77 thousand.
- What's Happening: Neogen recently reported better-than-expected Q2 results.
- What Neogen Does: Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety.
- 貿易: 新基公司 NEOG) 首席運營官愛德華·道格拉斯·瓊斯 買入總共二千五百股 平均價格為 17.91 美元。要收購這些股票,其成本約為 44.77 萬美元。
- 發生了什麼事: Neogen 最近報告的第二季度結果好於預期。
- 什麼新元做: Neogen Corporation 總部位於密歇根州蘭辛,致力於開發、製造和銷售各種食品和動物安全產品。
Check This Out: Investor Optimism Declines As Nasdaq Snaps 7-Day Win Streak
看看這個: 納斯達克捕捉 7 天連勝,投資者樂觀情緒下跌
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧